fexofenadine has been researched along with Chronic Illness in 19 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 9.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU)." | 9.12 | The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. ( Harding, G; Leahy, MJ; Meeves, S; Shikiar, R; Spector, SL, 2007) |
| "In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo." | 9.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "This dose-finding study assessed the safety and efficacy of fexofenadine in chronic idiopathic urticaria." | 9.09 | Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. ( Mason, J; Nelson, HS; Reynolds, R, 2000) |
| "The effect of 60 mg twice-daily fexofenadine HCl on health-related quality of life and productivity at work, in the classroom, and during daily activities in patients with moderate to severe chronic idiopathic urticaria symptoms was studied in two identical, 4-week, placebo-controlled, multicenter clinical trials." | 9.09 | Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. ( Finn, AF; Schoenwetter, WF; Thompson, AK, 2000) |
| "fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy." | 7.70 | Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000) |
| "To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU." | 6.71 | Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. ( Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005) |
| "Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks." | 6.70 | Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. ( Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001) |
| "Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo." | 6.70 | [Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. ( Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002) |
| "Urticaria is a common clinical condition that gives a major concern for physicians and patients alike." | 5.56 | Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria. ( Akhter, F; Jahan, H; Nandi, AK, 2020) |
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 5.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "The present study examined the impact of once-daily fexofenadine hydrochloride (HCl) 180 mg on health-related quality of life (HRQL) in subjects with chronic idiopathic urticaria (CIU)." | 5.12 | The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. ( Harding, G; Leahy, MJ; Meeves, S; Shikiar, R; Spector, SL, 2007) |
| "In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo." | 5.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "This dose-finding study assessed the safety and efficacy of fexofenadine in chronic idiopathic urticaria." | 5.09 | Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. ( Mason, J; Nelson, HS; Reynolds, R, 2000) |
| "The effect of 60 mg twice-daily fexofenadine HCl on health-related quality of life and productivity at work, in the classroom, and during daily activities in patients with moderate to severe chronic idiopathic urticaria symptoms was studied in two identical, 4-week, placebo-controlled, multicenter clinical trials." | 5.09 | Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. ( Finn, AF; Schoenwetter, WF; Thompson, AK, 2000) |
| "fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy." | 3.70 | Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. ( Jarvis, B; Simpson, K, 2000) |
| "To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU." | 2.71 | Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. ( Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005) |
| "Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks." | 2.70 | Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. ( Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001) |
| "Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo." | 2.70 | [Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients]. ( Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002) |
| "Urticaria is a common clinical condition that gives a major concern for physicians and patients alike." | 1.56 | Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria. ( Akhter, F; Jahan, H; Nandi, AK, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 14 (73.68) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Jahan, H | 1 |
| Akhter, F | 1 |
| Nandi, AK | 1 |
| Tanizaki, H | 2 |
| Nakahigashi, K | 1 |
| Miyachi, Y | 2 |
| Kabashima, K | 2 |
| Koh, SJ | 1 |
| Kim, JW | 1 |
| Kim, BG | 1 |
| Lee, KL | 1 |
| Chun, J | 1 |
| Kim, JS | 1 |
| Yamamoto, Y | 1 |
| Nakamizo, S | 1 |
| Otsuka, A | 1 |
| Chowdhury, BA | 1 |
| Cassano, N | 1 |
| Filotico, R | 1 |
| D'Argento, V | 1 |
| Filieri, M | 1 |
| Coviello, C | 1 |
| Vena, G | 1 |
| Kawashima, M | 1 |
| Harada, S | 1 |
| Tango, T | 1 |
| Lennox, RD | 2 |
| Leahy, MJ | 2 |
| Shikiar, R | 2 |
| Harding, G | 2 |
| Leahy, M | 1 |
| Kaplan, AP | 2 |
| Spector, SL | 2 |
| Meeves, S | 2 |
| Liao, Y | 1 |
| Varghese, ST | 1 |
| Georges, G | 1 |
| Finn, AF | 2 |
| Fretwell, R | 1 |
| Qu, R | 1 |
| Long, J | 1 |
| Simpson, K | 1 |
| Jarvis, B | 1 |
| Nelson, HS | 1 |
| Reynolds, R | 1 |
| Mason, J | 1 |
| Thompson, AK | 1 |
| Schoenwetter, WF | 1 |
| Nettis, E | 1 |
| Dambra, P | 1 |
| D'Oronzio, L | 1 |
| Loria, MP | 1 |
| Ferrannini, A | 1 |
| Tursi, A | 1 |
| Amichai, B | 1 |
| Grunwald, MH | 1 |
| Brenner, L | 1 |
| Kulthanan, K | 1 |
| Gritiyarangsan, P | 1 |
| Sitakalin, C | 1 |
| Charuwichitratana, S | 1 |
| Korkij, W | 1 |
| Aunhachoke, K | 1 |
| Janjumratsang, P | 1 |
| Jiamton, S | 1 |
| Kuntiranont, M | 1 |
| Krisadapong, J | 1 |
| Gherunpong, N | 1 |
| Kullavanijaya, P | 1 |
| Degonda, M | 1 |
| Pichler, WJ | 1 |
| Bircher, A | 1 |
| Helbling, A | 1 |
2 reviews available for fexofenadine and Chronic Illness
| Article | Year |
|---|---|
Review of fexofenadine in the treatment of chronic idiopathic urticaria.
Topics: Anti-Allergic Agents; Asia; Chronic Disease; Humans; North America; Terfenadine; Urticaria | 2002 |
Fexofenadine hydrochloride--a new anti-histaminic drug.
Topics: Chronic Disease; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Pati | 2001 |
11 trials available for fexofenadine and Chronic Illness
| Article | Year |
|---|---|
Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Ant | 2013 |
Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.
Topics: Adult; Anti-Allergic Agents; Chronic Disease; Cross-Over Studies; Dibenzoxepins; Female; Histamine H | 2015 |
Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.
Topics: Chronic Disease; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Histamine H1 An | 2004 |
Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Child; Chronic Disease; Double-Blind Method; Female; Humans; Male; Terfenadine; Urticari | 2005 |
The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria.
Topics: Adolescent; Chronic Disease; Double-Blind Method; Efficiency; Female; Histamine H1 Antagonists, Non- | 2007 |
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonis | 1999 |
Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Chronic Disease; Disorders of Excessive Somnol | 2000 |
Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Male; Middle Age | 2000 |
Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
Topics: Acetates; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blind Method; Female; Histamine H1 Ant | 2001 |
Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Histamine H1 Antagonists; Human | 2001 |
[Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients].
Topics: Adult; Aged; Anti-Allergic Agents; Chronic Disease; Double-Blind Method; Female; Humans; Male; Middl | 2002 |
6 other studies available for fexofenadine and Chronic Illness
| Article | Year |
|---|---|
Efficacy of Fexofenadine in the Treatment of Chronic Idiopathic Urticaria.
Topics: Adolescent; Bangladesh; Chronic Disease; Chronic Urticaria; Double-Blind Method; Humans; Terfenadine | 2020 |
Fexofenadine regulates nuclear factor-κB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates acute and chronic colitis in mice.
Topics: Acute Disease; Animals; Chronic Disease; Colitis; Endoplasmic Reticulum Stress; Female; HCT116 Cells | 2015 |
Chronic urticaria and angioedema.
Topics: Angioedema; Chronic Disease; Histamine H1 Antagonists; Humans; Terfenadine; Urticaria | 2002 |
In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Biopsy, Needle; Case-Control Studies; Chronic Disease; Culture Techniques; E-Sele | 2002 |
Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Clinical Trials, Phase III as Topic; Data Interpret | 2005 |
Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.
Topics: Administration, Oral; Adolescent; Adult; Anti-Allergic Agents; Chronic Disease; Dose-Response Relati | 2000 |